News
INVO Bioscience Announces Closing of Financing
SARASOTA, Fla., June 29, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...
INVO Bioscience Now Trading Under “INVO” Ticker Symbol On Tuesday, June 23, 2020
SARASOTA, Fla., June 23, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), ("the Company") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo...
A Vista Partners Interview with Steve Shum CEO of INVO Bioscience Regarding Increasing Access to Care for Fertility Treatment
Currently, it is estimated that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treatedSARASOTA, Fla., June 19, 2020 /PRNewswire/ -- Today, Steve Shum, Chief Executive Officer of INVO Bioscience, Inc. (OTCQB: INVO) (OTCQB:...
INVO Bioscience Announces 1-for-20 Reverse Stock Split
SARASOTA, Fla., May 22, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...
INVO Bioscience Reports First Quarter 2020 Financial Results
Company to Participate in Virtual Investor Conference on May 20 at 2:00pm ET (Details Below)SARASOTA, Fla., May 15, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed...
INVO Bioscience Appoints Christopher Myer as VP Business Development – Americas
SARASOTA, Fla., April 2, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on treating infertility with its FDA-cleared INVOcell® product, announced today the appointment of Christopher A. Myer as Vice President Business...
INVO Bioscience Reports 2019 Financial Results
SARASOTA, Fla., March 30, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...
INVO Bioscience Changes Trading Symbol to “INVO” Effective March 16, 2020
INVO's novel, FDA-cleared INVOcell technology provides an in-vivo incubation solution which can help increase access and capacity to the large underserved global fertility marketSARASOTA, Fla., March 16, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO)...